Related by context. Frequent words. (Click for all words.) 78 refractory chronic lymphocytic 75 refractory peripheral T 72 relapsed refractory multiple myeloma 71 leukemia CLL 71 cutaneous T cell 70 gastrointestinal stromal tumors GIST 70 refractory multiple myeloma 69 HER2 positive metastatic breast 69 lymphoma CTCL 69 forodesine 69 Epratuzumab 69 Amrubicin 68 luteinizing hormone releasing 68 Metastatic Melanoma 68 leukemia ALL 68 metastatic hormone refractory 68 relapsed multiple myeloma 68 refractory Hodgkin lymphoma 67 Panzem R 67 Belimumab 67 metastatic castrate resistant 67 multiple myeloma MM 67 Bortezomib 67 DOXIL 66 Pegasys ® 66 Voreloxin 66 Pivotal Phase III 66 romidepsin 66 metastatic castration resistant 66 Initiate Phase 66 Lenalidomide 66 cell chronic lymphocytic 66 Chronic Hepatitis C 66 CIMZIA TM 66 oropharyngeal candidiasis 66 registrational trial 66 liposomal formulation 66 Chronic Lymphocytic Leukemia 66 Gemzar ® 65 Genasense ® 65 sunitinib malate 65 Kuvan R 65 AEG# 65 Relapsed 65 J Am Acad 65 Acute Myeloid Leukemia AML 65 HGS ETR1 65 Pivotal Phase 65 mRCC 65 REVLIMID lenalidomide 65 plus dexamethasone 65 Single Dose 65 recurrent glioblastoma 65 II Clinical Trial 65 Traficet EN 65 Ixempra 65 EGFR expressing metastatic colorectal 65 ThermoDox R 64 ongoing Phase 1b 64 Ambrisentan 64 Recombinant Human 64 imatinib mesylate 64 REVLIMID R 64 primary hypercholesterolemia 64 mTOR inhibitor 64 TACI Ig 64 Orphan Drug status 64 EGFR expressing mCRC 64 virus HCV infection 64 phase Ib 64 relapsed refractory 64 Fibrillex TM 64 cell acute lymphoblastic 64 Phase III Clinical Trial 64 Proxinium TM 64 anticancer compound 64 Natalizumab 64 pegylated interferon alpha 64 fumarate 64 R sorafenib tablets 63 carcinoid syndrome 63 docetaxel chemotherapy 63 metastatic renal cell carcinoma 63 INCB# [001] 63 pertuzumab 63 Phase 2a trial 63 Dapagliflozin 63 Metastatic Colorectal Cancer 63 KNS # 63 Idiopathic Pulmonary Fibrosis 63 Nexavar ® 63 platinum refractory 63 plus prednisone 63 relapsing multiple sclerosis 63 DAVANAT 63 voriconazole 63 Golimumab 63 phase IIb clinical 63 Irinotecan 63 refractory PTCL 63 rilonacept